Figure 2b (row 836) illustrates a trial (NCT02401347) for the drug talazoparib which targets the gene CHEK2 for triple negative breast cancer patients. In conjunction with DrugBank, the cancer drug XL844 (DB05149) is also identified to inhibit CHEK2. Here, CHEK2 is linked to triple-negative breast carcinoma.